Diabetes Mellitus Is a Chronic Disease that Can Benefit from Therapy with Induced Pluripotent Stem Cells.

International Journal of Molecular Sciences
Felipe ArroyaveFernando Lizcano

Abstract

Diabetes mellitus (DM) is one of the main causes of morbidity and mortality, with an increasing incidence worldwide. The impact of DM on public health in developing countries has triggered alarm due to the exaggerated costs of the treatment and monitoring of patients with this disease. Considerable efforts have been made to try to prevent the onset and reduce the complications of DM. However, because insulin-producing pancreatic β-cells progressively deteriorate, many people must receive insulin through subcutaneous injection. Additionally, current therapies do not have consistent results regarding the prevention of chronic complications. Leveraging the approval of real-time continuous glucose monitors and sophisticated algorithms that partially automate insulin infusion pumps has improved glycemic control, decreasing the burden of diabetes management. However, these advances are facing physiologic barriers. New findings in molecular and cellular biology have produced an extraordinary advancement in tissue development for the treatment of DM. Obtaining pancreatic β-cells from somatic cells is a great resource that currently exists for patients with DM. Although this therapeutic option has great prospects for patients, some chal...Continue Reading

References

Nov 1, 1992·Biotechnology Progress·M R Ladisch, K L Kohlmann
Feb 11, 1983·Science·I S Johnson
Feb 1, 1995·Diabetic Medicine : a Journal of the British Diabetic Association·K M MacLeodB M Frier
Jan 26, 1996·The Journal of Biological Chemistry·S SharmaM R Montminy
Nov 6, 1998·Science·J A ThomsonJ M Jones
Mar 4, 2000·Proceedings of the National Academy of Sciences of the United States of America·G GradwohlF Guillemot
Dec 12, 2002·Diabetes·Danielle MelloulErol Cerasi
Oct 1, 2003·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Alan HartHelena Edlund
Jun 24, 2004·Reviews in Endocrine & Metabolic Disorders·Andrea M Vincent, Eva L Feldman
Aug 6, 2004·Endocrine Reviews·Andrea M VincentEva L Feldman
Jun 2, 2005·The Journal of Biological Chemistry·Steven G GrayFernando Dangond
Jul 7, 2005·Nature Reviews. Immunology·Christopher A Hunter
Aug 27, 2005·Diabetes·Monica TetaJake A Kushner
Nov 1, 2005·Nature Biotechnology·Kevin A D'AmourEmmanuel E Baetge
Oct 21, 2006·Nature Biotechnology·Kevin A D'AmourEmmanuel E Baetge
Sep 21, 2007·Endocrine Reviews·Mette Christine JørgensenJacob Hecksher-Sørensen
Dec 15, 2007·Nature Protocols·Kazutoshi TakahashiShinya Yamanaka
Feb 15, 2008·Diabetes Care·Alin O Stirban, Diethelm Tschoepe
Jun 5, 2008·The Journal of Biological Chemistry·Amanda M VanhooseRoland Stein
Aug 30, 2008·Nature·Qiao ZhouDouglas A Melton
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 27, 2008·The EMBO Journal·Makoto TachibanaYoichi Shinkai
Nov 22, 2008·Cold Spring Harbor Symposia on Quantitative Biology·D PasiniK Helin
May 12, 2009·Nature Genetics·Jeffrey C BarrettUNKNOWN Type 1 Diabetes Genetics Consortium
Dec 4, 2009·Current Diabetes Reports·Julia M Steinke
Feb 27, 2010·Cells, Tissues, Organs·Ronan O'Rahilly, Fabiola Müller
Jul 21, 2010·Nature·K KimG Q Daley
Jan 12, 2011·Advances in Experimental Medicine and Biology·Masato Nakagawa, Shinya Yamanaka
Feb 8, 2011·Lancet·Mariel M FinucaneUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Body Mass Index)
Feb 22, 2011·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Fong Cheng Pan, Chris Wright
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
Apr 19, 2011·Developmental Cell·Sangeeta DhawanAnil Bhushan

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
transgenic
acetylation

Clinical Trials Mentioned

NCT02939118

Related Concepts

Related Feeds

Antidiabetic Cellular Plasticity

This feed focuses on mechanisms that underlie cellular plasticity as a treatment for diabetes and other degenerative diseases.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.